Search
Seattle, WA Paid Clinical Trials
A listing of 1240 clinical trials in Seattle, WA actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1225 - 1236 of 1240
There are currently 1240 clinical trials in Seattle, Washington looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Washington, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center and University of Washington Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Crohn's Disease Clinical Study
Recruiting
Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.
Conditions:
Crohn's Disease
Crohn Disease
Crohns Disease
Crohn's Disease (CD)
Crohn Colitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Depressive disorder Clinical Study
Recruiting
A clinical study for people that suffer with Depressive disorder
Conditions:
Depressive disorder
Rare and Atypical Diabetes Network
Recruiting
RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes.
The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to:
1. Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes.
2. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypi... Read More
Gender:
ALL
Ages:
All
Trial Updated:
09/14/2022
Locations: Seattle Children's, Seattle, Washington +1 locations
Conditions: Diabetes Mellitus, Diabetes Mellitus Progression, Glucose Intolerance, Glucose Metabolism Disorders, Metabolic Disease, Endocrine; Complications, Endocrine System Diseases
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Condition or disease:
Breast Cancer
Intervention/treatment:
Drug: Gedatolisib
Drug: Palbociclib
Drug: Fulvestrant
Drug: Alpelisib
Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: Seattle Cancer Care Alliance, Seattle, Washington
Conditions: Breast Cancer
The Emergency Department Longitudinal Integrated Care
Recruiting
Collaborative care is a comprehensive patient-centered model of healthcare delivery targeting behavioral health or substance use that stems from the chronic disease management framework. The intervention being tested ('Emergency Department Longitudinal Integrated Care' or ED LINC) derives from the collaborative care model and has demonstrated feasibility in previous studies.
This study expands on the model to test the effectiveness of the ED-LINC intervention when compared with usual care. The... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2022
Locations: Harborview Medical Center, Seattle, Washington
Conditions: Opioid Use Disorder
International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors
Recruiting
Partial nephrectomy (PN) is the standard treatment for localized renal masses and should be preferred in clinical T1 (\<7 cm tumor diameter) renal tumors over radical nephrectomy (RN) whenever technically feasible. Nonetheless, indications, approaches, techniques for PN, and correct reporting of outcomes, are still a matter of great debate within the urology community. Concurrently, case-report series suggested that alternative strategies for the treatment of localized renal tumors (ablation tec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2022
Locations: Swedish Hospital, Seattle, Washington
Conditions: Kidney Cancer
Unobtrusive Sensing of Medication Intake ("USE-MI")
Recruiting
The purpose of this study is to test the USE-MI system hardware and software to see if it can accurately measure when subjects take their HIV-related medications and help them remember to take these medications. With the use of a smartwatch and smartphone "app", investigators hope to be able to monitor medication adherence in real-time and send subjects electronic reminders when they may have forgotten to take their medication.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2022
Locations: Swedish Medical Center, Seattle, Washington
Conditions: Medication Adherence
SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection
Recruiting
This study aims to test the effectiveness of using of SpeeDx Resistance Plus assay to guide treatment of Neisseria gonorrhoeae (Ng) in a sexual health clinic setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/09/2022
Locations: Public Health -- Seattle & King County Sexual Health Clinic, Seattle, Washington
Conditions: Neisseria Gonorrhoeae Infection
Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension
Recruiting
The purpose of this study is to evaluate the safety, efficacy, and usability of an eyedrop bottle adaptor that creates smaller eyedrops, Nanodropper, in an open-angle glaucoma/ocular hypertension patient population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2022
Locations: University of Washington, Seattle, Washington
Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
Recruiting
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
01/14/2022
Locations: Research Site, Seattle, Washington
Conditions: Chronic Lymphocytic Leukemia
Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19
Recruiting
The purpose of the study is to design and execute a prospective, longitudinal, descriptive cohort study in a pragmatic clinical practice for adults with symptoms that may be related to COVID-19.
Gender:
ALL
Ages:
Between 18 years and 114 years
Trial Updated:
09/27/2021
Locations: Seattle Intstitute of East Asian Medicine, Seattle, Washington
Conditions: Coronavirus Infection
Fecal Microbiota Transplantation as a Strategy to Eradicate Resistant Organisms
Recruiting
This protocol will evaluate fecal microbiota transplantation (FMT) as a strategy to eradicate intestinal colonization of extended-spectrum resistant (ESC-R) Enterobacteriaceae in pediatric patients.
FMT will be performed on subjects with a history of at least one infection due to ESC-R Enterobacteriaceae.
This protocol aims to determine the feasibility, safety, tolerability, and potential efficacy of FMT in pediatric patients with a history of ESC-R Enterobacteriaceae.
Gender:
ALL
Ages:
Between 7 years and 21 years
Trial Updated:
09/22/2021
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Infection Resistant to Drugs
Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients
Recruiting
The use of implantable left ventricular assist devices (LVAD) has increased over the last decade; partly because the newer continuous flow pumps feature a smaller design and better durability. These pumps have shown improved outcomes for those patients who don't qualify for heart transplantation and receive the LVAD device as a permanent therapy or a bridge to heart transplantation. Despite these improved outcomes, procedure related length of hospitalization for LVAD implantation is still 2 or 3... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2021
Locations: University of Washington Medical Center, Seattle, Washington
Conditions: Tricuspid Regurgitation, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The present study D5272C00001 (Legacy # 3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/19/2021
Locations: Research Site, Seattle, Washington
Conditions: Ulcerative Colitis
1225 - 1236 of 1240